Upper-limb dysfunction—pain, reduced shoulder mobility, weakness and activity limitation—remains common after breast cancer treatment. The review authors followed the PRISMA 2020 statement and searched four databases without date restrictions to identify randomized or quasi-randomized trials of interventions that included Proprioceptive neuromuscular facilitation (PNF) in women treated for breast cancer. The study team included only English-language trials and assessed risk of bias with the Cochrane RoB 2 tool and certainty of evidence with GRADE.
Investigators identified six trials enrolling a total of 366 women. PNF most often appeared as one component of multimodal rehabilitation programs rather than as a stand-alone intervention. The between-group contrast isolated PNF in four trials; in the remainder, PNF was embedded among other therapeutic elements, limiting attribution of effects to PNF alone.
Three trials specifically enrolled women with confirmed breast cancer-related lymphedema (BCRL). Across those trials, limb volume decreased in all study arms. The trial reports indicated no consistent superiority of PNF-containing interventions over active comparators for limb-volume reduction. The authors noted that in the context of BCRL, PNF was evaluated alongside decongestive strategies in some studies, and that PNF should not be presented as a substitute for established decongestive treatment.
The review found that the independent effect of PNF on BCRL remains unproven. The source did not report standardized PNF dosing parameters across BCRL trials (for example, specific progression schemes, session frequency or duration), and the authors explicitly called for trials using standardized PNF protocols in populations with confirmed lymphedema.
Three trials enrolled women without BCRL. In those studies, single trials reported improvements in shoulder range of motion, strength and functional measures associated with PNF-containing programs. The study team observed that these positive signals came from isolated trials rather than consistent replication across multiple trials, and that multimodal program components again complicate causal attribution.
The authors reported that where PNF was contrasted directly against active controls, some trials still found ROM and strength benefits; however, certainty around magnitude and durability of those benefits was low. The source did not provide pooled effect sizes or meta-analytic estimates; data synthesis was qualitative because of heterogeneity in interventions and outcomes.
Risk-of-bias appraisal found heterogeneity across the six trials. The authors judged one trial as low risk of bias, one as high risk, and four as of some concern. Using GRADE, the certainty of evidence was rated low or very low for the outcomes examined. The review team emphasized that small sample sizes, variable trial design, lack of standardized PNF protocols and multimodal interventions contributed to downgrading certainty.
The article noted that some trials isolated PNF in the between-group contrast, which strengthened internal validity in those specific comparisons, but overall methodological limitations restricted confidence in the published results. The source did not present detailed adverse-event profiles related specifically to PNF, and safety reporting appeared limited across trials.
The authors concluded that Proprioceptive neuromuscular facilitation may be a promising component of multimodal rehabilitation for upper-limb dysfunction after breast cancer treatment, but that independent effectiveness and effects on breast cancer-related lymphedema are unproven. They recommended that PNF should complement, rather than replace, established decongestive treatment in women with BCRL.
Specifically, the review called for randomized trials that: enroll women with confirmed BCRL; apply standardized, clearly described PNF protocols (the reviewed trials lacked consistent dosing and procedural detail); and include robust outcomes related to limb volume, shoulder range of motion, strength, function and safety. The source also registered the systematic review in PROSPERO (CRD42025641774) and reported that trial registration was retrospective.
Limitations reported by the authors included low trial numbers, heterogeneity of interventions and outcomes, and variable risk of bias across studies. The review did not specify regulatory milestones. Open clinical questions left by the source are concrete: what is the independent effect size of standardized PNF protocols on limb volume and function in confirmed BCRL, how durable are any benefits, and what are the safety and tolerability signals when PNF is combined with decongestive therapy? Trials addressing those questions are needed.